Back to top
more

Hologic (HOLX)

(Real Time Quote from BATS)

$68.02 USD

68.02
159,620

+0.21 (0.31%)

Updated Aug 18, 2025 10:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (152 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hologic (HOLX) Gets EUA for Its Coronavirus Detecting Test

by Zacks Equity Research

Hologic (HOLX) receives support from the government as a EUA for its molecular test to detect novel coronavirus on its Panther Fusion system.

Zacks Equity Research

Here's Why You Should Add Hologic Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on its strong segmental performance in Q1.

Zacks Equity Research

Hologic (HOLX) Down 12.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Hologic Expands Panther Portfolio With New Product Offerings

by Zacks Equity Research

Hologic's (HOLX) latest offerings are set to improve flexibility and efficiency of laboratories.

Zacks Equity Research

Here's Why You Should Hold on to Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on its strong segmental and international results in Q1.

Zacks Equity Research

Hologic (HOLX) Q1 Earnings Meet, Revenues Beat Estimates

by Zacks Equity Research

Hologic (HOLX) exhibits robust growth in first-quarter fiscal 2020, fueled by strong performance in the majority of its segments.

Zacks Equity Research

Hologic (HOLX) Matches Q1 Earnings Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 0.00% and 0.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products' Earnings Due on Jan 29: ALGN, HOLX & More

by Urmimala Biswas

A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.

Zacks Equity Research

Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?

by Zacks Equity Research

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.

Zacks Equity Research

Hologic (HOLX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Hologic (HOLX) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Hologic (HOLX) gains from several positive developments.

Sanghamitra Saha headshot

6 Sector ETFs & Stocks to Watch on December U.S. Inflation

by Sanghamitra Saha

These sector ETFs and stocks should benefit from decent price gains in the month of December.

Zacks Equity Research

Hologic Posts Solid Preliminary Q1 Sales, Revises Buyback Plan

by Zacks Equity Research

Hologic (HOLX) expects to generate robust Surgical and Diagnostics revenues in Q1, though softness in the divested Medical Aesthetics business remains a concern.

Zacks Equity Research

DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Hologic (HOLX) Divests Cynosure to Focus on Women's Health

by Zacks Equity Research

Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.

Zacks Equity Research

Hologic (HOLX) Up 13.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Hologic (HOLX) to Showcase Health Solutions Portfolio at RSNA

by Zacks Equity Research

Hologic (HOLX) to highlight its latest offerings in its breast health portfolio at the ongoing annual RSNA meet.

Zacks Equity Research

Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark

by Zacks Equity Research

Hologic (HOLX) wins the CE Mark for long-term use of LOCalizer RFID tag, providing more flexibility to breast-conserving surgery.

Zacks Equity Research

Hologic (HOLX) Set to Divest Medical Aesthetics Business

by Zacks Equity Research

Hologic (HOLX) to sell off its medical aesthetics business to focus on other core segments.

Zacks Equity Research

Hologic's (HOLX) 3DQuorum Imaging Technology Gets FDA Nod

by Zacks Equity Research

The regulatory clearance is likely to boost Hologic's (HOLX) Breast and Skeletal Health Solutions business segment.

Zacks Equity Research

Hologic's Aptima Genitalium Assay Gets Clinically Verified

by Zacks Equity Research

This study result is expected to be a major stride forward in Hologic's (HOLX) commitment toward strengthening its Diagnostic Solutions business.

Zacks Equity Research

Hologic's (HOLX) Q4 Earnings Meet, Revenues Top Estimates

by Zacks Equity Research

Hologic (HOLX) exhibits robust fourth-quarter growth fueled by strong segmental performance.

Zacks Equity Research

Hologic (HOLX) Q4 Earnings Match Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 0.00% and 2.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Can Segmental Growth Aid Hologic (HOLX) in Q4 Earnings?

by Zacks Equity Research

Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.

Urmimala Biswas headshot

Impressive Near-Term Outlook for Medical Instruments Industry

by Urmimala Biswas

Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.